Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
This study has been completed.
Study NCT00170781.   Last updated on November 29, 2006.
Information provided by Novartis
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Gouty Arthritis
Additional conditions recognized in this trial
Arthritis
Arthritis, Gouty
More general conditions related to this trial
Genetic Diseases, Inborn
Gout
Joint Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Musculoskeletal Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Rheumatic Diseases
Interventions listed in this trial
Lumiracoxib
Additional drug interventions recognized in this trial
Prexige
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Novartis


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services